Argenx SE: financial analysis
Ratios worked out from 10 fiscal years of Argenx SE's statements, compared with 670 companies in Biotechnology.
Argenx SE scorecard#
Passes 8 of the 10 checks that could be worked out: strongest in growth (4 of 4), weakest in profitability (4 of 5). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth4 of 4
- ✓Revenue grew in the newest year89.9%Revenue up 89.9% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year19.57 vs 12.78Diluted EPS 19.57 in fiscal 2025 against 12.78 the year before (report's currency).
- ✓Net income higher than five years earlier$1.3 B$1.3 B in fiscal 2025 against -$608 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$1.3 BNet income $1.3 B in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median25.4%25.4% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%20.1%20.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier25.4%25.4% in fiscal 2025 against -7181.9% in 2022.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (esef, sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 3 years in a row.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio rosenot on file
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseyes
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 25.4% | -1.0% | — | — | -70.1% | -60.5% | 89% | |
| Net margin | 31.1% | 38.1% | -830.4% | — | -82.1% | -68.9% | 88% | |
| Return on equity | 20.2% | 17.4% | -8.5% | -26.5% | -19.4% | -61.0% | 94% | |
| Return on assets | 17.4% | 15.5% | -7.7% | -23.7% | -15.9% | -44.4% | 95% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 89.9% | — | 254.2% | — | — | 15.8% | 81% | |
| Revenue growth, 3 years a year | — | — | — | — | 169.7% | 12.9% | — | |
| Revenue growth, 5 years a year | — | — | — | — | 98.2% | 15.4% | — | |
| Net income growth | 55.1% | — | — | — | — | 10.1% | 73% | |
| Earnings per share growth | 53.1% | — | — | — | — | 7.6% | 69% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Current ratio | — | — | — | — | — | 4.39× | — | |
| Equity share of assets | 84.3% | 88.7% | 90.2% | 89.8% | 88.9% | 64.3% | 76% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $679 M | $-85 M | $-421 M | $-864 M | $-610 M | $-40 M | 98% | |
| Free cash flow margin | 16.4% | -3.9% | — | — | -122.8% | -61.5% | 83% | |
| Cash conversion | 53.0% | -9.9% | — | — | — | 72.6% | 46% | |
| Capital spending share of revenue | 0.2% | 0.1% | 2.3% | 8.4% | 0.7% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.56× | 0.41× | 0.01× | 0.00× | 0.19× | 0.26× | 75% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Asset turnover
- Revenue divided by total assets (average of the year).